Skip to content Skip to left sidebar Skip to right sidebar Skip to footer

Tag: #GenomeValley

Syneos Health Opens Global Life Sciences Centre in Hyderabad

Hyderabad, September 24, 2026 – In a major boost to India’s biopharmaceutical and technology landscape, Syneos Health, a leading fully integrated biopharmaceutical solutions organization, has officially inaugurated its new Global Life Sciences and Technology Centre in Hyderabad.

Spanning an impressive 137,000 square feet, this state-of-the-art facility is now the company’s largest centre in Asia and its third-largest globally, signaling a massive vote of confidence in Hyderabad’s burgeoning life sciences ecosystem.

Scale and Scope of the New Centre

The newly opened facility is designed to be a powerhouse of innovation and operational excellence. Key highlights of the centre include:

  • Robust Initial Workforce: The centre launches with an initial team of over 700 highly skilled professionals, with aggressive plans for expansion in the coming years.
  • End-to-End Capabilities: The hub brings together diverse, high-value functions under one roof, including clinical development, commercialization, medical affairs, advanced technology, Artificial Intelligence (AI), and core corporate functions.
  • Global Leadership Presence: Unlike traditional offshore delivery centers, this facility will house global leaders and cross-functional teams working directly from Hyderabad to drive drug development and commercialization strategies for clients worldwide.

A Strategic Shift: Beyond the Traditional Delivery Model

This inauguration marks a pivotal evolution in how global life sciences companies view India. Syneos Health is actively positioning its Hyderabad hub not merely as a back-office support center, but as a strategic growth hub.

By embedding global leadership and advanced AI/engineering capabilities locally, Syneos Health is leveraging India’s deep talent pool to co-create solutions, accelerate clinical timelines, and drive innovation for the global biopharma market.

Leadership Perspectives

The centre was inaugurated by D. Sridhar Babu, Minister for IT and Industries of Telangana, alongside a distinguished delegation of Syneos Health executives, including:

  • Mike Montello, Chief Digital and Information Officer
  • Tom Wollman, Head of Operational Excellence
  • Jinu Jose, General Manager, India and Strategic Growth Hubs
  • Harpreet Bedi, Chief Technology Officer
  • Madhuri Raya, Global Head, AI and Engineering and Technology Capability Centre

Highlighting the synergy between the state’s vision and the company’s goals, Minister D. Sridhar Babu stated:

“Hyderabad has built one of India’s strongest life sciences ecosystems and one of its deepest technology talent pools. The next opportunity is to bring these strengths together with AI. We are moving from a city where medicines are made and services are delivered to a city where the future of healthcare and life sciences is being built. With an end-to-end ecosystem spanning APIs, bulk drugs, generics, CDMO, vaccines, research and discovery, and a growing concentration of global healthcare and biotech GCCs, Hyderabad has the talent and depth to become a global testbed for AI-enabled life sciences.”

Strategic Impact on Hyderabad’s Life Sciences Ecosystem

The establishment of this centre reinforces Hyderabad’s position as the “Genome Valley” of India and a premier global destination for Global Capability Centres (GCCs) in healthcare. The strategic impacts include:

  1. High-Value Job Creation: Attracting top-tier talent in clinical research, data science, AI, and biopharma commercialization.
  2. AI and Tech Integration: Accelerating the adoption of Artificial Intelligence and advanced analytics in drug discovery and clinical trial management within the region.
  3. Ecosystem Validation: Further validating Hyderabad’s comprehensive life sciences value chain, which already spans active pharmaceutical ingredients (APIs), vaccines, contract development and manufacturing (CDMO), and cutting-edge R&D.

Looking Ahead

As Syneos Health scales its operations in Hyderabad, the centre is poised to become a critical nerve center for the company’s global operations. By fusing deep domain expertise in life sciences with cutting-edge technology and AI, Syneos Health is not just expanding its footprint—it is actively helping to build the future of global healthcare from the heart of India.

Amgen to Establish New Science and Innovation Centre in Hyderabad’s Genome Valley

Global biopharmaceutical giant Amgen is doubling down on its commitment to India, announcing plans to open a state-of-the-art Science and Innovation Centre in Hyderabad’s premier Genome Valley. Slated to become operational in 2027, this new facility will mark a significant expansion of Amgen’s global research and development (R&D) network, which currently comprises seven research laboratories worldwide.

Bridging Wet-Lab Science and Digital Innovation

The new Hyderabad centre is designed to be a powerhouse of discovery. It will focus on critical, high-impact areas including:

  • Discovery Chemistry
  • Drug Metabolism and Pharmacokinetics (DMPK)
  • Precision Medicine
  • Data Science and Digital Technologies

By integrating experimental “wet-lab” science with advanced data analytics and AI-driven tools, the centre aims to dramatically accelerate the discovery and development of life-saving medicines. This facility will seamlessly complement Amgen’s existing Global Capability Centre (GCC) in Hyderabad, creating a powerful synergy between digital innovation and hands-on biological research.

Why Hyderabad? A Thriving Life Sciences Ecosystem

Hyderabad has long been recognized as India’s “Genome Valley,” but this new investment signals a shift from manufacturing and clinical research to high-value, early-stage discovery.

D. Sridhar Babu, Telangana’s Minister for IT and Industries, praised the decision, highlighting the state’s robust ecosystem: “Hyderabad brings together scientific talent, technology, and industry at scale and has built one of the world’s strongest life sciences ecosystems, with deep capabilities in pharmaceuticals and vaccines. The next chapter is about taking that strength into discovery and innovation. Our ambition is to make Hyderabad a place where the next generation of medicines and therapies can be discovered, developed, and taken to the world.”

Leadership Perspectives on Global Integration

For Amgen, this move is about creating a truly interconnected global R&D footprint.

Jay Bradner, Executive Vice President of Research and Development, Artificial Intelligence, and Data at Amgen, noted that the Genome Valley centre will perfectly complement the company’s strong US-based R&D operations. It will expand Amgen’s ability to connect science, data, and technology across its global research system, translating complex insights into tangible new medicines.

Som Chattopadhyay, Senior Vice President of Global Business Solutions and National Executive at Amgen, emphasized that this development firmly establishes India as a critical, strategic pillar in Amgen’s global R&D network.

Echoing this sentiment, Naveen Gullapalli, Managing Director of Amgen India, highlighted the region’s human capital: “Hyderabad’s STEM talent and life sciences ecosystem will support advanced technologies at scale. Our new centre at Genome Valley will help integrate biotechnology and digital innovation to serve more patients globally.”

Looking Ahead

Amgen’s investment in Hyderabad is a resounding vote of confidence in India’s scientific prowess and its potential to drive global healthcare innovation. As the centre gears up for its 2027 launch, it promises to create high-value jobs, foster cutting-edge research, and cement Hyderabad’s status as a premier global destination for biotech discovery and digital health innovation.

The future of medicine is being written in Hyderabad, and Amgen is ready to lead the next chapter.